Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04398953 | A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL) | unknown | Phase 2 | 102 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04544059 | Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 87 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Sep 10, 2020 |
| NCT04514081 | The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. | unknown | Phase 2 | 200 | Chinese PLA General HospitalOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT04516655 | A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients(C-R-HDMTX) | unknown | Phase 2 | 51 | Fudan UniversityOTHER | 0 | Aug 18, 2020 | clinicaltrials |
| NCT04233294 | Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma | unknown | Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04510610 | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | unknown | Phase 2 / Phase 3 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT04500561 | YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial | unknown | Phase 1 / Phase 2 | 28 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 5, 2020 | clinicaltrials |
| NCT03669445 | Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma(IFM2018-01) | unknown | Phase 2 | 45 | University Hospital, ToulouseOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT03778619 | MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin | unknown | Phase 1 / Phase 2 | 9 | GC Cell CorporationINDUSTRY | 1 | Jul 28, 2020 | clinicaltrials |
| NCT03474133 | Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)(BASALT) | unknown | Phase 2 | 80 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jul 21, 2020 | clinicaltrials |
| NCT04470141 | A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma | unknown | Phase 2 | 130 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 0 | Jul 14, 2020 | clinicaltrials |
| NCT04324879 | A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) | unknown | Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04453345 | TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL | unknown | Phase 2 / Phase 3 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT03363555 | SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma | unknown | Phase 2 | 97 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 18, 2020 | clinicaltrials |
| NCT04425824 | Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 20 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT03544723 | Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. | unknown | Phase 2 | 40 | MultiVir, Inc.INDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04120350 | R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty(REMLA) | unknown | Phase 1 / Phase 2 | 47 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT04405375 | GPED Regimen for Relapsed/Refractory or Advanced ENKTCL | unknown | Phase 2 | 29 | Beijing Tongren HospitalOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04370405 | A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma | unknown | Phase 2 | 123 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | May 11, 2020 | clinicaltrials |
| NCT04279379 | Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma | unknown | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 1 | May 7, 2020 | clinicaltrials |
| NCT04379167 | A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma | unknown | Phase 2 | 140 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | May 7, 2020 | clinicaltrials |
| NCT04338282 | Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma | unknown | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 0 | Apr 8, 2020 | clinicaltrials |
| NCT04337593 | Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL | unknown | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 0 | Apr 7, 2020 | clinicaltrials |
| NCT04337606 | Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02733380 | Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 1, 2020 | clinicaltrials |
| NCT04306887 | A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL) | unknown | Phase 2 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02951728 | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma(DR-CHOP) | unknown | Phase 1 / Phase 2 | 58 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT03600363 | A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients | unknown | Phase 2 | 250 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT04096690 | Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma | unknown | Phase 2 | 22 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT02533700 | CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL | unknown | Phase 2 | 106 | Shandong Provincial HospitalOTHER_GOV | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00276783 | Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases | unknown | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT04296786 | Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study | unknown | Phase 2 | 52 | Peking Union Medical College HospitalOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT03385096 | Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT02918747 | PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage | unknown | Phase 2 | 100 | Hunan Cancer HospitalOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT02267915 | Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT(MAN2) | unknown | Phase 2 | 36 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04206943 | Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL(ISIKOK-19) | unknown | Phase 1 / Phase 2 | 24 | Acibadem UniversityOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04239170 | Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 84 | Peking UniversityOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT03977103 | Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT | unknown | Phase 2 | 80 | University Of PerugiaOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04163575 | Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL | unknown | Phase 1 / Phase 2 | 100 | Kecellitics Biotech Company LtdINDUSTRY | 0 | Dec 23, 2019 | clinicaltrials |
| NCT02856048 | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer(PRESOV) | unknown | Phase 2 / Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04023916 | Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 0 | Dec 11, 2019 | clinicaltrials |
| NCT03527628 | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy((Optimist)) | unknown | Phase 2 | 220 | King Abdullah International Medical Research CenterOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04162119 | Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT03746223 | Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Oct 9, 2019 | clinicaltrials |
| NCT02060656 | Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)(LEGEND) | unknown | Phase 2 | 92 | Royal Marsden NHS Foundation TrustOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT03018405 | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications(THINK) | unknown | Phase 1 / Phase 2 | 146 | Celyad Oncology SAINDUSTRY | 2 | Sep 19, 2019 | clinicaltrials |
| NCT03497533 | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19(Trident19-H) | unknown | Phase 1 / Phase 2 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT04066920 | IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL | unknown | Phase 2 | 30 | Deok-Hwan YangOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT04065308 | Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma(Dara_DCEP) | unknown | Phase 2 | 33 | Seoul National University HospitalOTHER | 1 | Aug 22, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Sep 11, 2020source: clinicaltrials